Chandra S, Popovic J, Singhal NK, Watkins EA, Dodiya HB, Weigle IQ, Salvo MA, Ramakrishnan A, Chen Z, Watson JT, Shetti A, Piehl N, Zhang X, Cuddy LK, Sadleir KR, Schwulst SJ, Prakriya M, Gate D, Sisodia SS, Vassar R. The gut microbiome controls reactive astrocytosis during Aβ amyloidosis via propionate-mediated regulation of IL-17. J Clin Invest. 2025 May 13; Epub 2025 May 13 PubMed.
Recommends
Please login to recommend the paper.
Comments
Washington University in St. Louis, School of Medicine
This is a beautiful and important study. It adds a new layer to our understanding of how the immune system communicates with the brain under homeostatic conditions. The idea that gut-primed T cells migrate to the subfornical organ and shape behavior via IFN-γ resonates strongly with our earlier findings (Filiano et al., 2016), where we showed a role for IFN-γ in regulating social behavior.
What’s exciting here is the clear identification of brain-resident T cells—not just in the meninges—and the evidence that they are transcriptionally distinct, CXCR6-positive, and behaviorally relevant. This work takes us another step past the old dogma of CNS immune privilege and pushes us to think more broadly about immune-derived signals as physiological modulators of brain function.
References:
Filiano AJ, Xu Y, Tustison NJ, Marsh RL, Baker W, Smirnov I, Overall CC, Gadani SP, Turner SD, Weng Z, Peerzade SN, Chen H, Lee KS, Scott MM, Beenhakker MP, Litvak V, Kipnis J. Unexpected role of interferon-γ in regulating neuronal connectivity and social behaviour. Nature. 2016 Jul 21;535(7612):425-9. Epub 2016 Jul 13 PubMed.
View all comments by Jonathan KipnisMassachusetts General Hospital
Massachusetts General Hospital/Harvard Medical School
Chandra et al. have demonstrated novel pathways through which the gut microbiome modulates brain pathology in Alzheimer’s disease. They also propose molecular mechanisms that could be targeted for therapeutic intervention. The highlight of this elegant study is its careful dissection of astrocytic reactivity in the context of Aβ pathology. While prior studies have mainly focused on microglial responses or amyloid deposition, Chandra et al. demonstrate a role for astrocytes in responding to gut-derived cues, most notably the short-chain fatty acid (SCFA), propionate.
Plasma metabolomics revealed a selective increase in propionate in antibiotic-treated mice, which negatively correlated with markers of astrocyte reactivity and positively with homeostatic astrocyte traits. Importantly, this increase was linked to elevated abundance of Akkermansia muciniphila, a gut commensal known to produce propionate. This association draws attention to the specific microbial contributors to neuroactive metabolite pools and highlights the potential of targeting select bacterial taxa to therapeutically modulate factors that cause brain inflammation.
The authors also show that direct administration of sodium propionate recapitulates the effects of broad-spectrum antibiotic treatment, suppressing astrocytic reactivity and reducing Aβ plaque burden—while sparing microglial function. These results argue that astrocytes are not passive bystanders but active integrators of microbial and immune signals, capable of shaping CNS pathology. Importantly, these neuroinflammatory changes were accompanied by increased levels of synaptic proteins, including synaptophysin and PSD-95, with propionate treatment. This suggests that reducing astrocytic reactivity may preserve, or even enhance, synaptic integrity—a vital consideration given the strong association between synapse loss and cognitive decline in AD. This finding adds a new layer to our understanding of how the gut microbiome can impact neurodegenerative processes beyond the realm of immune activation and amyloid deposition.
By linking propionate exposure to the suppression of peripheral Th17 cell differentiation and IL-17A production, the authors also identify a novel immune-metabolic axis that bridges gut microbial metabolites with CNS inflammation. Using IL-17A monoclonal antibody treatment, they show that the effects of propionate on reducing astrocyte reactivity and Aβ pathology are IL-17-dependent. These experiments underscore how modulation of a single metabolite—propionate—can critically influence CNS inflammatory pathways via T-cell mediated immune responses.
From a translational perspective, the identification of a naturally occurring microbial metabolite that ameliorates AD pathology opens new therapeutic possibilities. Propionate—or microbial consortia and dietary strategies designed to enhance SCFA production—could represent a new class of adjunct therapies aimed at modifying disease progression by targeting gut-CNS communication.
This study challenges the microglia-centric view of AD by highlighting astrocytes as independent, microbiota-responsive immune players, urging a more integrated perspective that bridges immunology and neurobiology.
In conclusion, Chandra et al. present a conceptually bold and methodologically rigorous study that advances our understanding of how peripheral systems influence CNS pathology in Alzheimer’s disease. Their identification of the propionate–IL-17–astrocyte axis represents an important advance in AD research. Future studies inspired by this work could explore how microbial ecology, dietary fiber intake, and targeted microbiome manipulation intersect with host immunity to affect brain aging and resilience to Alzheimer’s disease and other neurodegenerative disorders.
View all comments by Nanda Kumar Navalpur ShanmugamMake a Comment
To make a comment you must login or register.